Recently, the US Food and Drug Administration (FDA) approved the launch of a concussion deep transcranial magnetic stimulation system for the treatment of obsessive-compulsive disorder (OCD).

Obsessive-compulsive disorder is a neurosis, referred to as obsessive-compulsive disorder, which is a type of neurological disorder characterized by repeated obsessions and forced movements. Obsessive-compulsive disorder is not uncommon in the clinical population, and its lifetime prevalence is 2%-3%. According to the National Institute of Mental Health, about 1% of American adults have OCD in the past year.

At present, there is no specific method for the treatment of obsessive-compulsive disorder. It is generally based on drug therapy and psychotherapy or a combination of the two. It is also reported in physical therapy such as electroconvulsive (ECT) and surgical treatment. Although most patients with obsessive-compulsive disorder respond to treatment, there are still some patients with symptoms.

The FDA-approved device is called the “brain sway deep transcranial magnetic stimulation system.” The system was approved based on a randomized, multicenter study of 100 patients, of which 49 patients received a concussion device. Treatment, 51 patients received treatment with a non-working (fake) device. Throughout the course of the study, the dose usually given by the patient was once every Friday, 20 minutes of treatment. Treatment lasts 4 to 6 weeks. The reduction in patient scores was assessed by using the Yale-Brown Obsessive-compulsive Disorder Scale (YBOCS) (YBOCS is a commonly used measure of the severity of obsessive-compulsive disorder in patients). The results showed that 38% of the patients in the experimental group had improved their condition. In the control group, only 11% of patients responded.

Transcranial Magnetic Stimulation (TMS) is a pulsed magnetic field that acts on the central nervous system (mainly the brain) to alter the membrane potential of cortical neurons, causing them to induce currents, affecting brain metabolism and nerve power. Activities that cause a series of physiological and biochemical reactions of magnetic stimulation techniques. As a painless, non-invasive method of cortical stimulation, it has been rapidly applied in the fields of psychiatry and neurology.

As early as 2008, transcranial magnetic stimulation (TMS) has been approved by the FDA for the treatment of adults with major depression who respond poorly to antidepressants, and in 2013 expanded the use of TMS to treat certain Pain caused by migraine.

Dr. Carlos Pena, Director of the Department of Neurology and Physical Medicine, Department of Instruments and Radiological Health, US Food and Drug Administration (FDA), said: "Transcranial magnetic stimulation has shown its potential to help people with depression and headaches, and is licensed in today's market. Under, those with obsessive-compulsive disorder who do not respond to traditional therapies now have another option."

The system can still avoid certain side reactions in the treatment of OCD. The main side effect in clinical trials is headache, and 37.5% of patients have symptoms of headache. The patient also felt mild discomfort in the place where the device was placed, as well as squat pain, facial pain, cramps, convulsions and neck pain, all of which quickly disappeared. In addition, the FDA official website warns patients with a history of epilepsy to discuss their medical history with health care providers before accepting the device.

The US Food and Drug Administration allows Brainsway Ltd. to sell such devices.

Extract Powder

China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer

Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com